“I’ve seen up markets, down markets. I’ve seen administrations change multiple times. But this is a tumultuous time. There’s no doubt about that.” – Founder of Alnylam Pharmaceutical and City Therapeutics John Maraganore on the resilience of industry in the face of a changing economic and political climate. Find out more: Reflections From Biotech Leader John Maraganore
“Tariffs, they’re not going to throw us off balance … we’ve dealt with net sales price declines the last six years, and we’ll continue to stay focused. If there’s some activity that comes through in tariffs, we’ll take it on and make sure we get these medicines through to patients who need them wherever they might be in the world.” –Amgen’s chief financial officer Peter Griffith on the company’s continued optimism, despite mounting regulatory uncertainty over newly implemented tariffs. Find out more: Amgen Optimistic About Growth, Despite Denosumab Biosimilars, Potential Tariffs
“I can’t predict the political situation, but I believe that each person has to faithfully carry out their work even in times of political and social uncertainties. However, the biopharma industry typically is affected relatively less than other industries.” – President of the Korea Pharmaceutical and Bio-Pharma Manufacturers Association (KPMA) Yunhong Noh on the stance of the new Trump administration and how certain policies may still pose issues for Korean firms. Find out more: Uncertain Times: Korean Pharma Braces For Trump, Political Turmoil
“So, it’s a fundamental component of how we do all clinical trials. I know the words get politicized right now in the US, which is unfortunate, but the science is clear - the best data is clinical research that represents all patients.” – Parexel’s CEO Peyton Howell on the value of clinical diversity following Trump’s call to end government programs around DEI initiatives. Find out more: Parexel Leaders On Trial Diversity, AI And What’s Holding Sponsors Back In India
“That aspiration to become a top-five company still remains … though there’s no magic to that number, it’s really just the position we have in other [major] markets where we operate, so we just want to perform in the US as we do elsewhere.” – Novartis’ US leader Victor Bulto on the company’s exceptional international growth in 2024 and hopes for the future as they look to become a more competitive US market. Find out more: Novartis’s Bulto: Kisqali Is Blueprint For More Competitive US Launches
“I think to be a modern oncology company and to have the ability to pursue areas of biologic conviction, you need different tools depending on what that conviction is.” – Lilly’s chief medical officer David Hyman on the company’s oncology strategies, appetite for deal-making and work they are driving to expand its cardiometabolic disease profile. Find out more: Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ in R&D
“We’ve had an unprecedented number of launches…and we believe that from now till the end of the decade, we have the potential to launch 10 new medicines and up to 30 new indications for the products that we have on the market. … In my over two decades with the company, I don’t think we’ve ever had as much substrate to work with as we have today with an incredibly robust pipeline.” – Bristol Myers Squibb’s chief commercialization officer Adam Lenkowsky on the company’s rapid growth and future catalysts, as it aims to account for upcoming losses of exclusivity. Find out more: BMS Enters A Catalyst-Rich Era Full Of Both LOE’s And New Launches
“While we not disclosing the new indications right now, we are working at full speed to have at least two to three other indications with this incredible asset – we are getting increasingly confident it is a pipeline in a drug with significant growth potential.” – Leo Pharma’s CEO Christophe Bourdon on the expected target date for the therapy from the US Food and Drug Administration for the third quarter of this year and future opportunities for Anzupgo. Find out more: Laser Profits Lifts Leo Pharma To Point Of Profitability
“The execution in terms of pricing and market access is going either according to plan or sometimes we’re passing expectations.” – Almirall’s CEO Carlos Gallardo on the company’s successful launches, for instance with Ebglyss, the product achieved reimbursement six months ahead of schedule alongside forecasted weekly sales. Find out more: Almirall Predicts Plenty More Growth In Psoriasis
“I do think there is a bit of a bottleneck in that space in between seed financing and where companies are going to be acquired … or go public, and that’s where we need to break the bottleneck if we’re really going to allow this to flow.” – Sena Therapeutics chairman Julia Owens on the missed market opportunity of women’s health and the struggle faced by companies to obtain early investments from venture investors. Find out more: Momentum In Women’s Health, But Big Obstacles Too
“Where pain continues to be an important component of business, and we have the field force which can handle these kinds of products. I think it’s both the attractiveness of the product for the regulated as well as in emerging markets.” – Sun Pharmaceutical Industries’ chief operating officer Aalok Shanghvi on emerging opportunities for Antibe’s asset otenaproxesul and the ongoing controversy around the use of opioids for chronic pain management. Find out more: Sun On Progressing Antibe’s Non-Opioid Analgesic Challenges in Japan